Endocrinologia Clínica (Lúcio Vilar) - 6 Edição_Parte140

Prévia do material em texto

70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
2011; 55:91-105.
Gullu BE, Celik O, Gazioglu N et al. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary.
2010; 13:242-8.
Santos MC, Nascimento GC, Nascimento AG et al. Thyroid cancer in patients with acromegaly: a case-control study.
Pituitary. 2013; 16:109-14.
Petroff D, Tönjes A, Grussendorf M et al. The incidence of cancer among acromegaly patients: results from the German
Acromegaly Registry. J Clin Endocrinol Metab. 2015; 100:3894-902.
Rajasoorya C, Holdaway IM, Wrightson P et al. Determinants of clinical outcome and survival in acromegaly. Clin
Endocrinol (Oxf). 1994; 41:95-102.
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;
89:667-74.
Katznelson L, Laws ER Jr, Melmed S et al.; Endocrine Society. Acromegaly: an endocrine society clinical practice
guideline. J Clin Endocrinol Metab. 2014; 99:3933-51.
Dimaraki IV, Jaffe CA, DeMott-Friberg R et al. Acromegaly with apparently normal GH secretion: implications for
diagnosis and follow-up. J Clin Endocrinol Metab. 2002; 87:3537-42.
Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab.
2000; 85:526-9.
Giustina A, Casanueva, FF, Cavagnini F et al.; The Pituitary Society and the European Neuroendocrine Association.
Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003; 26:1242-7.
Trainer PS. Acromegaly consensus, what consensus? J Clin Endocrinol Metab. 2002; 87:3534-6.
Giustina A, Chanson P, Bronstein MD et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;
95:3141-8.
Ribeiro-Oliveira Jr A, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically-active
acromegaly. Eur J Endocrinol. 2011; 164:17-22.
Rosario PW. Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol.
2010; 54:477-81.
Hekimsoy Z, Yunten N, Sivrioglu S. Coexisting acromegaly and primary empty sella syndrome. Neuro Endocrinol Lett.
2004; 25:307-9.
Osella G, Orlandi F, Caraci P et al. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with
empty sella. J Endocrinol Invest. 2003; 26:163-9.
Guerini MB, Barbato MT, Sá NB et al. Pachydermoperiostosis: the complete form of the syndrome. An Bras Dermatol.
2011; 86:582-4.
Chakraborty PP, Bhattacharjee R, Mukhopadhyay S et al. Pseudoacromegaly in pachydermoperiostosis. BMJ Case Rep.
2016; 2016.
Bergmann C, Wobser M, Morbach H et al. Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar
hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol. 2011; 20:531-3.
Zhang Z, He JW, Fu WZ et al. Two novel mutations in the SLCO2A1 gene in a Chinese patient with primary hypertrophic
osteoarthropathy. Gene. 2014; 534:421-3.
Shimizu C, Kubo M, Kijima H et al. A rare case of acromegaly associated with pachydermoperiostosis. J Endocrinol Invest.
1999; 22:386-9.
Nguyen KH, Marks JG Jr. Pseudoacromegaly induced by the long-term use of minoxidil. J Am Acad Dermatol. 2003;
48:962-5.
Sam AH, Tan T, Meeran K. Insulin-mediated “pseudoacromegaly”. Hormones (Athens). 2011; 10:156-61.
	Endocrinologia Clínica (Lúcio Vilar) - 6ª Edição